Спутнік V (Belarusian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Спутнік V" in Belarusian language version.

refsWebsite

Global rank Belarusian rank

4^th place

66^th place

2^nd place

22^nd place

1rosminzdrav.ru

low place

5,588^th place

1businesstimenow.com

low place

low place

220^th place

755^th place

businesstimenow.com

"Russia's approval of a COVID-19 vaccine is less than meets the press release". 2020-08-11. Праверана 2020-08-13. {{cite news}}: Шаблон цытавання ўжывае састарэлы параметр |authors= (даведка)

cnbc.com

"Scientists worry whether Russia's Sputnik V' coronavirus vaccine is safe and effective". CNBC. 11 August 2020. Праверана 2020-08-11. {{cite news}}: Шаблон цытавання ўжывае састарэлы параметр |authors= (даведка)

doi.org

Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, et al. (2020-09-14). "Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia". Lancet. 396 (10255): 887–897. doi:10.1016/S0140-6736(20)31866-3. PMC 7471804. PMID 32896291.
Mahase E (August 2020). "Covid-19: Russia approves vaccine without large scale testing or published results". BMJ. 370: m3205. doi:10.1136/bmj.m3205. PMID 32816758.

nih.gov

pubmed.ncbi.nlm.nih.gov

Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, et al. (2020-09-14). "Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia". Lancet. 396 (10255): 887–897. doi:10.1016/S0140-6736(20)31866-3. PMC 7471804. PMID 32896291.
Mahase E (August 2020). "Covid-19: Russia approves vaccine without large scale testing or published results". BMJ. 370: m3205. doi:10.1136/bmj.m3205. PMID 32816758.

ncbi.nlm.nih.gov

Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, et al. (2020-09-14). "Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia". Lancet. 396 (10255): 887–897. doi:10.1016/S0140-6736(20)31866-3. PMC 7471804. PMID 32896291.

rosminzdrav.ru

grls.rosminzdrav.ru

Official data on the vaccine and its manufacturers on the website of the state registration of medicines of the Ministry of Health of Russia